Compare Moderna, Inc. (MRNA) vs ABRDN Physical Gold Shares ETF (SGOL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs ABRDN Physical Gold Shares ETF — how do they compare? Moderna, Inc. trades at $63.94 (market cap $24.18B), while ABRDN Physical Gold Shares ETF trades at $41.95. The key difference: Moderna, Inc. is trading nearer its 52-week high, ABRDN Physical Gold Shares ETF nearer its low. Which is the better fit depends on your goals.
| MRNA | SGOL | |
|---|---|---|
Market Cap | $24.18B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $81.80 | $51.41 |
52-Week Low | $22.36 | $31.61 |
Enterprise Value | $20.33B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $63.57, up 6.29% on the day, reflecting positive momentum following FDA approval of its mRNA flu vaccine, mFLUSIVA, for adults 50 and older. The stock exhibits a bullish technical outlook with moving averages supporting upward movement, though RSI levels suggest potential overbought conditions. Fundamentally, revenue has declined from pandemic peaks, with 2025 revenue at $1.92B and a net loss of -$2.82B, yet the company has beaten EPS estimates in recent quarters. Cash flow trends show improvement, with net cash flow turning positive in 2025 at $668M.
The outlook for MRNA hinges on pipeline execution beyond COVID-19, with recent vaccine approvals providing growth catalysts. Investment opportunities include diversification into flu, Ebola, and oncology therapies, but risks persist from high cash burn, competitive pressures, and reliance on successful clinical trials. Analyst sentiment is mixed with a consensus price target of $54.33, below the current price, indicating caution despite some bullish developments.
SGOL trades at $42.21, up 0.98% with a bullish technical signal from moving averages, though oscillators show caution with RSI at overbought levels. The gold ETF benefits from recent CPI data showing cooling inflation and strong central bank demand, with spot gold prices testing key resistance levels. Financial ratios remain unavailable for this commodity-focused ETF structure.
The outlook remains positive given gold's momentum and macroeconomic support, though overbought conditions suggest potential near-term consolidation. Key risks include Fed policy shifts and dollar strength, while institutional buying provides underlying support for the gold thesis.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About ABRDN Physical Gold Shares ETF
SGOL is an ETF that is designed to track the performance of the price of gold bullion. The fund is backed by physical gold held in secured vaults, which is allocated to the ETF's custodian account. By providing direct ownership of gold without the need for physical storage or insurance, SGOL offers investors a convenient and cost-effective way to gain exposure to the gold market.
Read more on SGOL →
